All News
RheumNow Podcast - ACR 2021 Rehash (the good stuff..)
The ACR 2021 meeting has concluded. Dr. Jack Cush recounts a few more great abstracts from this past week’s virtual meeting.
Read Article
Psoriatic Arthritis: "What Matters" to Patients, Physicians
A study presented today by Mease et al. addresses the vital gap between what patients and physicians consider disabling because of PsA, and emphasizes “what matters” in a daily clinical encounter while dealing with PsA.
Read Article
ACR21 Best Abstracts - Day 4
On the last day of ACR21 Annual Meeting, the RheumNow faculty selected these 15 as their favorite reports.
Read Article
ACR21 – Day 3 Report
Hitting the home stretch, day 3 presentations were big! Here are a few of my favorites: secukinumab efficacy in juvenile PsA; VEXAS - predicting poor outcomes; and the FDA Safety Update session.
Read Article
Monitoring Infliximab Drug Levels Improves Efficacy
Should we start considering therapeutic drug monitoring when prescribing TNFi for treatment of our rheumatologic conditions?
Read Article
Psoriatic Arthritis: What's with Brepocitinib? Dr. Eric Ruderman ( @JointMD ) discusses abstract #0488 presented at the #ACR21 annual meeting.
https://t.co/mq0IMwyMSk https://t.co/oJAJS0DpQz
Links:
Dr. John Cush RheumNow ( View Tweet)
Targeting the HUGE dilemma!🎯
#Psoriatic vs Erosive #OA
PsA
👉 Fluffy bone formation(enthesitis of phalanges)
👉 Marginal erosions(vs central)
👉 Many jts in same digit(ray inv)
👉 Periarticular SOFT tissue swelling (dactylitis).
👉 NOT much hand OA
#ACR21 RadiologyBootCamp https://t.co/OQLPoeRLny
Ashima Makol MD AshimaMakol ( View Tweet)
Upadacitinib PsA w/axial involvement - post-hoc analysis of SELECT-PsA 1 and S-PsA-2
Statistically greater response in axial dz compared to placebo in both dz dx'ed by investigator alone & on investigator + PRO-based criteria
https://t.co/YPc5fx9wAR
#ACR21 Abst1945 @RheumNow
Pedro Castillo _Castillo_Pedro ( View Tweet)
Dr. Alexis Ogdie on opioid use in PsA and axSpA, highlighting need for better interventions.
🔹21% of PsA pts (n=828) and 27% of axSpA (n=334) reported prescription opiate use.
🔹⬆️BASDI & HAQ-DI =>⬆️opiate use & costs
https://t.co/Id658ocDVf
#ACR21 Abst1777 @RheumNow
Pedro Castillo _Castillo_Pedro ( View Tweet)
⭐️From 2012 – 2017 NIS data significant 🔽 in sepsis, SSTI, and UTI in patients with PsA despite the increased use of biologics over the years
⭐️No statistical difference pneumonia trend in PsA
Abst# 1783 #ACR21 @Rheumnow https://t.co/ToxgRb0acP
swethaann23 swethaann23 ( View Tweet)
Direct-to-Patient (DA) PsA Screening Survey sent to patients with Ps without PsA led to earlier diagnosis of PsA in 0.4%(n=1149 patients) as compared to 0.3%(n=1150) receiving standard of care (SOC).
Mean times to PsA diagnosis
66d ▶️ DA
77d ▶️SOC
Abst# 1781 #ACR21 @RheumNow https://t.co/qxjPCU0vnI
swethaann23 swethaann23 ( View Tweet)
Hospitalisation for heart failure ⬆️ in inflammatory diseases. RA>PsA>AS>PsO . HRs 1.1-1.6 compared to general population. Abstr#1925 #ACR21 @RheumNow https://t.co/kKlGQM5Tcg
Richard Conway RichardPAConway ( View Tweet)
Why is there more CHF in #RheumatoidArthritis ? Also dose response between highest inflammation RA the PsA then axSpA then PsO. ?Cytokine profile varying with disease and maybe CRP. Who knows. Abst#1925 #ACR21 @RheumNow https://t.co/JIH3qwkLpx
Janet Pope Janetbirdope ( View Tweet)
Should we be measuring drug levels in pts taking infliximab?
⭐️Drug monitoring vs. standard dosing showed 73% sustained control vs. 55% (RA, PsA, SpA, UC, Crohn's, PsO)
#ACR21
Abs#1946
#ACRBest @RheumNow
https://t.co/sWMen50ljP https://t.co/F4Wpqis3id
Links:
Robert B Chao, MD doctorRBC ( View Tweet)
Prospective study of PsO screened @ derm clinics
🔹PsO➕>3 mo back pain starting <45yo➕no biologics➡️rheum ref, 100 pts seen➡️19 dx'ed as:
🔹14 axPsA, 68% met axSpA ASAS, 11/14 w/o pPsA
🔹5 pPsA w/o axial dz
https://t.co/azoks5CHCP
#ACR21 Abst#1796 @RheumNow
Pedro Castillo _Castillo_Pedro ( View Tweet)
Elevated CRP levels (>3) in PsA associated with ⬆️risk of cardiovascular events
⭐️NSAID use significantly REDUCED risk of CV events
Abs#1920
#ACR21 @RheumNow
https://t.co/gIz9f4SlWo https://t.co/V4uDeO3Iuz
Links:
Robert B Chao, MD doctorRBC ( View Tweet)
Racial differences in PsA patients in large US real world database
95% Whites (W) and 5% were AA
NSAIDs: 80% W and 78% AAs
TNFI: 51% W and 41% of AAs
DMARDs: 72% of W and 98% of AAs
HTN/DM/Obesity/Gout 🔼 AA
Cancer/osteoporosis /anxiety 🔼 whites
Abst#1780 #ACR21 @Rheumnow https://t.co/7ee4bVU7ZA
swethaann23 swethaann23 ( View Tweet)
PsO vs PsA patient and disease characteristics COPPAR registry:
PsO pts 🔼mean BSA
Both 🔼 % of biologic therapy
sPGA and PASI 🔼PsO
🔽QOL and physical health in PsA
🔼daily work impairment PsA
Abst # 1779 #ACR21 @RheumNow
swethaann23 swethaann23 ( View Tweet)
⭐️Ustekinumab+MTX vs. UST+PBO in PsA?
➡️Additional MTX has no positive impact on UST efficacy for arthritis, enthesitis, dactylitis, skin, QoL, & function.
*️⃣Thus, no evident to add or maintain ongoing MTX when starting UST
Late-Breaking Poster#12. #ACR21 @RheumNow #ACRBest https://t.co/k96PPUtwct
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
Retrospective cohort study FORWARD databank :
⭐️ 🔼opioid use was associated with higher HAQ-DI and BASDAI scores among patients with PsA or AS
Annualized avg opioid use and costs 🔼with 🔼HAQ-DI and BASDAI scores for patients in both cohorts
Abst#1117 #ACRBest @RheumNow https://t.co/KB9QUITbAe
swethaann23 swethaann23 ( View Tweet)
